Form 13-F position report

PHIO PHARMACEUTICALS CORP

Reported by MORGAN STANLEY

PHIO CUSIP 71880W303 Manager CIK 0000895421

Reported 0 shares, down 1,500 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q1 2023
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 10 Through Q1 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 2000
2022-03-31 0
2022-06-30 0
2022-09-30 0
2022-12-31 558
2023-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

6 quarters
Quarterly reported position history for PHIO PHARMACEUTICALS CORP held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2023 Reduced 0 -1,500 (-100.0%) 0 $0 2023-05-15
Q4 2022 Added 1,500 +1,498 (74900.0%) < 0.01% $558 2023-02-14
Q3 2022 New 2 +2 (0.0%) 0 $0 2022-11-14
Q2 2022 Reduced 0 -7 (-100.0%) 0 $0 2022-08-15
Q1 2022 Reduced 7 -1,494 (-99.5%) 0 $0 2022-05-13
Q4 2021 Added 1,501 +1 (0.1%) < 0.01% $2,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

13 managers reported PHIO PHARMACEUTICALS CORP for Q1 2023.

Managers reporting PHIO PHARMACEUTICALS CORP in Q1 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
CONCOURSE FINANCIAL GROUP SECURITIES INC Unchanged 0 0 0 $0 13 qtrs
BlackRock Inc Reduced 0 -19 0 $0 13 qtrs
Cetera Investment Advisers Reduced 0 -75,000 0 $0 7 qtrs
JPMorgan Chase & Co Reduced 0 -50 0 $0 3 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 0 -106,917 0 $0 10 qtrs
TWO SIGMA SECURITIES LLC Reduced 0 -19,707 0 $0 8 qtrs
TWO SIGMA INVESTMENTS LP Reduced 0 -22,398 0 $0 8 qtrs
Tower Research Capital LLC TRC Reduced 0 -5,220 0 $0 4 qtrs
MORGAN STANLEY This report Reduced 0 -1,500 0 $0 10 qtrs
WELLS FARGO & COMPANY MN Reduced 0 -93 0 $0 13 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2023
Filed
May 15, 2023
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.